GLP-1受体激动剂和胆囊疾病风险:洞察分子机制和临床影响
Mariana M Ramírez-Mejía1,2, Guadalupe Ponciano-Rodriguez3, Mohammed Eslam4
1Plan of Combined Studies in Medicine, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.
Therapeutic advances in endocrinology and metabolism
|December 29, 2025
概括
类似葡萄糖-1受体激动剂 (GLP-1RAs) 改善糖尿病和肥胖管理. 然而,它们可能会增加胆囊疾病的风险,促使需要新的管理策略.
科学领域:
- 内分泌学 在内分泌学.
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 类似葡萄糖-1受体激动剂 (GLP-1RAs) 对2型糖尿病和肥胖管理至关重要.
- 它们的有效性源于通过增强胰岛素分泌,减少葡萄糖和延迟胃排空来改善葡萄糖控制和减肥.
研究的目的:
- 探索将GLP-1RA与增加胆囊疾病风险联系在一起的机制.
- 引入一种新的算法,用于管理GLP-1RAs患者的胆汁风险.
主要方法:
- 审查潜在的机制,包括胆囊托基宁抑制,胆酸受体信号,以及肠-大脑通路的改变.
- 为GLP-1RA用户开发一个风险管理算法.
主要成果:
- GLP-1RA与胆固醇胆病和胆囊炎的风险增加有关.
- 潜在的机制涉及胆道系统和肠-大脑轴内的复杂相互作用.
结论:
- 虽然GLP-1RA对代谢障碍有好处,但会带来胆道并发症的风险.
- 建议采用积极的算法方法来缓解这些风险.
相关概念视频
Glucagon-like Receptor Agonists
816
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
816
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
501
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
501
Dipeptidyl Peptidase 4 Inhibitors
547
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
547
Oral Hypoglycemic Agents: Glinides
560
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
560
Acute Pancreatitis II: Clinical Manifestations and Management
699
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
699
Oral Hypoglycemic Agents: Biguanides and Glitazones
559
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
559


